PT  - JOURNAL ARTICLE
AU  - Muniz-Rodriguez, Kamalich
AU  - Chowell, Gerardo
AU  - Cheung, Chi-Hin
AU  - Jia, Dongyu
AU  - Lai, Po-Ying
AU  - Lee, Yiseul
AU  - Liu, Manyun
AU  - Ofori, Sylvia K.
AU  - Roosa, Kimberlyn M.
AU  - Simonsen, Lone
AU  - Viboud, Cecile
AU  - Fung, Isaac Chun-Hai
TI  - Doubling Time of the COVID-19 Epidemic by Chinese Province
AID  - 10.1101/2020.02.05.20020750
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.05.20020750
4099  - http://medrxiv.org/content/early/2020/04/24/2020.02.05.20020750.short
4100  - http://medrxiv.org/content/early/2020/04/24/2020.02.05.20020750.full
AB  - COVID-19 epidemic doubling time by Chinese province was increasing from January 20 through February 9, 2020. The harmonic mean of the arithmetic mean doubling time estimates ranged from 1.4 (Hunan, 95% CI, 1.2-2.0) to 3.1 (Xinjiang, 95% CI, 2.1-4.8), with an estimate of 2.5 days (95% CI, 2.4-2.6) for Hubei.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program. ICHF acknowledges salary support from the National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (19IPA1908208). This article is not part of ICHF’s CDC-sponsored projects.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data analyzed is publicly available aggregated data. The data is provided in the Technical Appendix.